Standout Papers
Citation Impact
Citing Papers
Review article: the global emergence of Helicobacter pylori antibiotic resistance
2015
Mechanisms underlying the resistance to diet-induced obesity in germ-free mice
2007 Standout
The gut microbiota influences blood-brain barrier permeability in mice
2014 Standout
Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases
2007 Standout
Obesity alters gut microbial ecology
2005 Standout
Metagenomic Analysis of the Human Distal Gut Microbiome
2006 StandoutScience
The gut microbiota and host health: a new clinical frontier
2015 Standout
Management of Helicobacter pylori infection—the Maastricht V/Florence Consensus Report
2016 Standout
Management of Helicobacter pylori infection—the Maastricht IV/ Florence Consensus Report
2012 Standout
Algae as nutritional and functional food sources: revisiting our understanding
2016 Standout
Microbiota in health and diseases
2022 Standout
Role of the normal gut microbiota
2015 Standout
Multiple sclerosis patients have a distinct gut microbiota compared to healthy controls
2016 Standout
Enteral Versus Parenteral Feeding Effects on Septic Morbidity After Blunt and Penetrating Abdominal Trauma
1992 Standout
Antibiotic resistance and CYP2C19 polymorphisms affect the efficacy of concomitant therapies forHelicobacter pyloriinfection: an open-label, randomized, single-centre clinical trial
2016
The Toronto Consensus for the Treatment of Helicobacter pylori Infection in Adults
2016
Changes of Intestinal Functions in Liver Cirrhosis
2016 Standout
Effects of anti-Helicobacter pylori concomitant therapy and probiotic supplementation on the throat and gut microbiota in humans
2017
Dietary emulsifiers impact the mouse gut microbiota promoting colitis and metabolic syndrome
2015 StandoutNature
Intestinal permeability and complications in liver cirrhosis: A prospective cohort study
2012
A New Modified Concomitant Therapy for Helicobacter pylori Eradication in Turkey
2011
Selective increases of bifidobacteria in gut microflora improve high-fat-diet-induced diabetes in mice through a mechanism associated with endotoxaemia
2007 Standout
A Randomized Controlled Study Comparing Reverse Hybrid Therapy and Standard Triple Therapy for Helicobacter pylori Infection
2015
Attempts to enhance the eradication rate ofHelicobacter pyloriinfection
2014
Gut biogeography of the bacterial microbiota
2015 Standout
Levofloxacin, bismuth, amoxicillin and esomeprazole as second-line Helicobacter pylori therapy after failure of non-bismuth quadruple therapy
2016
Systematic review with meta‐analysis: the efficacy of levofloxacin triple therapy as the first‐ or second‐line treatments of Helicobacter pylori infection
2016
A Comparative Study of Sequential Therapy and Standard Triple Therapy for Helicobacter pylori Infection: A Randomized Multicenter Trial
2014
Kyoto global consensus report onHelicobacter pylorigastritis
2015 Standout
Prospective multi-region study on primary antibiotic resistance of Helicobacter pylori strains isolated from Chinese patients
2014
Induction of Intestinal Th17 Cells by Segmented Filamentous Bacteria
2009 Standout
Altered intestinal tight junctions’ expression in patients with liver cirrhosis: a pathogenetic mechanism of intestinal hyperpermeability
2011
Concomitant, sequential, and hybrid therapy for H. pylori eradication: A pilot study
2013
Local and systemic mechanisms linking periodontal disease and inflammatory comorbidities
2021 Standout
Empirical modified sequential therapy containing levofloxacin and high-dose esomeprazole in second-line therapy for Helicobacter pylori infection: a multicentre clinical trial
2011
Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: a proof-of-concept exploratory study
2019 Standout
Nonbismuth Quadruple (Concomitant) Therapy: Empirical and Tailored Efficacy versus Standard Triple Therapy for Clarithromycin‐Susceptible Helicobacter pylori and versus Sequential Therapy for Clarithromycin‐Resistant Strains
2012
Specific Microbiota Direct the Differentiation of IL-17-Producing T-Helper Cells in the Mucosa of the Small Intestine
2008 Standout
Acute-on-chronic liver failure: terminology, mechanisms and management
2016
Short-term probiotic therapy alleviates small intestinal bacterial overgrowth, but does not improve intestinal permeability in chronic liver disease
2014
Global eradication rates for Helicobacter pylori infection: systematic review and meta-analysis of sequential therapy
2013
Review article: non-bismuth quadruple (concomitant) therapy for eradication of Helicobater pylori
2011
Targeting gut-liver axis for the treatment of nonalcoholic steatohepatitis: translational and clinical evidence
2015
Randomized Clinical Trial: Esomeprazole, Bismuth, Levofloxacin, and Amoxicillin or Cefuroxime as First-Line Eradication Regimens for Helicobacter pylori Infection
2017
Helicobacter pyloritherapy: Present and future
2012
Rational Helicobacter pylori Therapy: Evidence-Based Medicine Rather Than Medicine-Based Evidence
2013
Impaired hepatic removal of interleukin-6 in patients with liver cirrhosis
2010
Prevalence of Antibiotic Resistance in Helicobacter pylori: A Systematic Review and Meta-analysis in World Health Organization Regions
2018 Standout
Helicobacter pylori: perspectives and time trends
2014
Assessment of Sequential and Standard Triple Therapy in Treatment of Helicobacter pylori Infection in Children Dependent on Bacteria Sensitivity to Antibiotics
2016
Randomized clinical trial comparing ten day concomitant and sequential therapies for Helicobacter pylori eradication in a high clarithromycin resistance area
2016
Influence of diet on the gut microbiome and implications for human health
2017 Standout
Actualización de la eficacia de la terapia triple para la infección por Helicobacter pylori y de la resistencia a claritromicina en España (2007-2012)
2013
Gastric cancer
2020 Standout
Fusobacterium nucleatum Promotes Colorectal Carcinogenesis by Modulating E-Cadherin/β-Catenin Signaling via its FadA Adhesin
2013 Standout
Review of antibiotic resistance in China and its environment
2017 Standout
Optimizing clarithromycin-containing therapy forHelicobacter pyloriin the era of antibiotic resistance
2014
A moderate weight reduction through dietary intervention decreases hepatic fat content in patients with non-alcoholic fatty liver disease (NAFLD): a pilot study
2012
Update on non-bismuth quadruple (concomitant) therapy for eradication of Helicobacter pylori
2012
Early Enteral Feeding, Compared With Parenteral, Reduces Postoperative Septic Complications The Results of a Meta-Analysis
1992 Standout
Guidelines for treatment ofHelicobacter pyloriin the East and West
2011
Burn injury
2020 Standout
ACG Clinical Guideline: Treatment of Helicobacter pylori Infection
2017
The relationship between the failure to eradicate Helicobacter pylori and previous antibiotics use
2015
Efficacy of genotypic resistance-guided sequential therapy in the third-line treatment of refractory Helicobacter pylori infection: a multicentre clinical trial
2012
Standard triple and sequential therapies for Helicobacter pylori eradication: An update
2012
NF-κB, inflammation, immunity and cancer: coming of age
2018 Standout
The pros, cons, and many unknowns of probiotics
2019 Standout
Ten‐day sequential versus triple therapy for H elicobacter pylori eradication: A prospective, open‐label, randomized trial
2012
Tailored versus Triple plus Bismuth or Concomitant Therapy as Initial Helicobacter pylori Treatment: A Randomized Trial
2015
Dialogue between E. coli free radical pathways and the mitochondria of C. elegans
2015 StandoutNobel
Microbial Translocation in Chronic Liver Diseases
2012
Overview of pharmacological activities ofAndrographis paniculataand its major compound andrographolide
2018 Standout
The Hidden World within Plants: Ecological and Evolutionary Considerations for Defining Functioning of Microbial Endophytes
2015 Standout
Intestinal permeability – a new target for disease prevention and therapy
2014 Standout
Comparison of Hybrid and Sequential Therapies for H elicobacter pylori Eradication in I ran: A Prospective Randomized Trial
2012
High antibiotic resistance of Helicobacter pylori and its effect on tailored and empiric eradication of the organism in Lower Silesia, Poland
2016
The inner of the two Muc2 mucin-dependent mucus layers in colon is devoid of bacteria
2008 Standout
Introduction to the human gut microbiota
2017 Standout
Proportion and number of cancer cases and deaths attributable to potentially modifiable risk factors in the United States
2017 Standout
Antibiotic resistance of Helicobacter pylori in Mashhad, Iran.
2013
Meta-Analysis of Sequential, Concomitant and Hybrid Therapy for <i>Helicobacter pylori</i> Eradication
2015
Inflammatory Bowel Disease
2010 Standout
Primary antibiotic resistance ofHelicobacter pyloristrains isolated from patients with dyspeptic symptoms in Beijing: A prospective serial study
2015
Clinical Evaluation of a Ten‐Day Regimen with E someprazole, M etronidazole, A moxicillin, and C larithromycin for the Eradication of H elicobacter pylori in a High Clarithromycin Resistance Area
2013
Optimised empiric triple and concomitant therapy forHelicobacter pylorieradication in clinical practice: the OPTRICON study
2015
First-line eradication rates comparing two shortened non-bismuth quadruple regimens againstHelicobacter pylori: an open-label, randomized, multicentre clinical trial
2015
Feasibility of Shortening 14‐day Hybrid Therapy While Maintaining an Excellent Helicobacter pylori Eradication Rate
2014
Intestinal epithelial barrier function in liver cirrhosis: an extensive review of the literature
2013
The First Microbial Colonizers of the Human Gut: Composition, Activities, and Health Implications of the Infant Gut Microbiota
2017 Standout
The Controversial Role of Human Gut Lachnospiraceae
2020 Standout
The Changing Profile of Helicobacter pylori Antibiotic Resistance in Singapore: A 15‐Year Study
2016
Hybrid Therapy as First‐Line Regimen for Helicobacter pylori Eradication in Populations with High Antibiotic Resistance Rates
2016
Silymarin/Silybin and Chronic Liver Disease: A Marriage of Many Years
2017 Standout
Concomitant and hybrid therapy for H elicobacter pylori infection: A randomized clinical trial
2015
Antimicrobial Susceptibility‐Guided Therapy Versus Empirical Concomitant Therapy for Eradication of Helicobacter pylori in a Region with High Rate of Clarithromycin Resistance
2015
Rabeprazole, Minocycline, Amoxicillin, and Bismuth as First‐Line and Second‐Line Regimens for Helicobacter pylori Eradication
2016
Review: Efficacy and Safety of Hybrid Therapy for Helicobacter pylori Infection: A Systematic Review and Meta‐analysis
2014
Works of Agnese Miranda being referenced
Empirical levofloxacin-containing versus clarithromycin-containing sequential therapy for Helicobacter pylori eradication: a randomised trial
2010
Optimized Nonbismuth Quadruple Therapies Cure Most Patients With Helicobacter pylori Infection in Populations With High Rates of Antibiotic Resistance
2013
Intestinal permeability in patients with chronic liver diseases: Its relationship with the aetiology and the entity of liver damage
2009
Efficacy of 5-Day Levofloxacin-Containing Concomitant Therapy in Eradication of Helicobacter pylori Infection
2012
242 14-Day, High-Dose Acid Suppression, Non-Bismuth Quadruple Therapies (Hybrid vs. Concomitant) for Helicobacter pylori Infection: A Randomized Trial
2013
OC.02.3 FOURTEEN-DAY, HIGH-DOSE ACID SUPPRESSION, NON-BISMUTH QUADRUPLE THERAPIES (“HYBRID” VS. “CONCOMITANT”) FOR HELICOBACTER PYLORI ERADICATION: A RANDOMISED TRIAL
2013